Table 2.
Noradrenaline, μM | Control | During EFS | During EFS +l-NOARG |
---|---|---|---|
0.1 | 1.4 ± 0.2 | 0.7 ± 0.2* | 1.8 ± 0.3 |
1 | 9.3 ± 1.8 | 4.2 ± 0.8* | 8.8 ± 1.7 |
10 | 35.9 ± 2.8 | 32.5 ± 2.7 | 38.3 ± 3.9 |
100 | 94.8 ± 3.4 | 90.3 ± 3.3 | 99.3 ± 0.7 |
The magnitude of contractions (shown as % of maximum contraction) elicited by exogenous noradrenaline (0.1–100 μM) in the rat anococcygeus muscle treated with guanethidine (10 μM) under control conditions, during EFS, and during EFS following l-NOARG (300 μM).
P < 0.05 vs. control value; n = 8.